Searched for
INCRED HEALTHCARE
PMS Tracker: Quant, fintech strategies lead December gains of up to 8%; Kotak, Aequitas among top performersQuant, fintech and diversified PMS strategies topped December’s charts with gains of up to 8%, even as several small-cap and thematic portf...- PMS Tracker: Top 15 funds gain over 10% in October; Sundaram, Kotak among biggest gainersAt least 15 PMS funds across small-cap, sectoral and multi-cap themes delivered stellar October returns, led by Sundaram Alternate Assets’ ...
- ChrysCapital, InCred invest in Amber subsidiary ILJIN ElectronicsILJIN Electronics India, an Amber Group subsidiary, secured ₹1,200 Crore in funding from ChrysCapital and InCred Growth Partners. ChrysCapi...
- Buy, Sell or Hold: Morgan Stanley initiates coverage on CG Power; Nuvama retains a buy on RILBrokerages are optimistic about specific large and mid-cap companies. Morgan Stanley initiates coverage on CG Power with an Overweight rati...
- TCS Q1 Results Preview: IT major may clock modest 3% profit growth; Trump tariffs impact in focusTata Consultancy Services (TCS) is set to announce Q1FY26 results on July 10, with brokerages estimating a 1-3% YoY net profit growth betwe...
- InCred hikes Nifty target by 4%; adds Axis Bank, UPL to High-Conviction ListDespite earnings downgrades and market volatility, InCred Equities has increased its Nifty target to 24,280, encouraged by lower crude oil ...
- Hospital stocks gain on safe-haven buyingIn past one month, most hospital stocks such as Max Healthcare, Apollo Hospitals, Fortis Healthcare, Healthcare Global and Rainbow Children...
- PMS Tracker FY25: 18 funds gain up to 54%, worst performers shed over 27%PMS strategies: In FY25, 18 PMS strategies posted over 20% gains, with InCred’s Focused Healthcare Portfolio topping at 53.6%. Healthcare a...
- Where is Nifty 50 headed by March 2026? InCred Equities flags further downsideNifty 50 has dropped 14% from its peak due to weak earnings, foreign outflows, and global trade concerns. InCred Equities lowered its targe...
- CCI clears merger of nine pharma entities with Sequent ScientificThe Competition Commission of India has approved the amalgamation of nine entities into Sequent Scientific Ltd (SSL), enhancing its positio...
- ETMarkets PMS Talk: Why InCred Healthcare PMS is overweight on hospitals and diagnostics for 2025InCred healthcare portfolio offers a structural investment product that invests in 5 different baskets of businesses like Branded Generics,...
- Hold Persistent Systems, target price Rs 6,863: InCred EquitiesInCred Equities maintains a 'hold' rating on Persistent Systems, raising the target price to Rs 6,863 from Rs 6,260. Strong performance in ...
- Fund Manager Talk | Aditya Khemka picks 4 sectors that are likely to outperform in Samvat 2081"Over the next 12 months, we expect Nifty to report low double-digit earnings growth YoY, however, we do not expect PE multiple for Nifty t...
- ETMarkets Smart Talk | Smart money moving to healthcare, FMCG, and IT: Aditya Khemka of InCred Asset ManagementFurthermore, while 1QFY25 earnings were largely below expectations, we observe that earnings growth expectations for the remainder of FY25 ...
- Trend of larger, more liquid hospital stocks getting more exorbitantly priced to continue: Aditya KhemkaAditya Khemka of InCred Healthcare PMS discusses the overvaluation of hospital stocks due to liquidity chasing the asset. Liquidity is driv...
- ETMarkets Fund Manager Talk | This CIO managing over $100 mn assets believes 2024 will be dominated by rural consumption"We believe that the market is likely to show return divergence across sectors. Earnings growth will not be broad based and, hence, stock s...
- Nifty may remain in consolidation mode till December. Here's why"With the recent geopolitical tensions raising the index volatility, we feel the index will remain range-bound in the short term and will l...
- Hot Stocks: Brokerage view on Apollo Hospitals, HEG, Tata Chemicals, Indigo and Dalmia BharatJPMorgan has started coverage of Apollo Hospitals as overweight, with a target price of INR 5,950 ($80). The bank has started coverage of F...
- FY24 should see improvement in margins for pharma sector: Aditya KhemkaHowever, in FY24 what we believe is that the government will again allow pharma companies to take price increases anywhere in the range of ...
- Manipal’s Ranjan Pai partners ex-Deutsche banker’s NBFCPai is partnering ex-Deutsche banker Bhupinder Singh's non-bank finance company where the German lender's former CEO Anshu Jain is a minori...
Load More
